iBio (IBIO) Income from Continuing Operations (2010 - 2026)
iBio (IBIO) posted quarterly Income from Continuing Operations of 7849000.0 for Q1 2026, down 58.63% year-over-year from 18972570.59 in Q1 2025, and up 13.68% quarter-over-quarter from 9093000.0 in Q4 2025.
iBio (IBIO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Income from Continuing Operations for 17 consecutive years, with 7849000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 58.63% year-over-year to 7849000.0; the TTM figure through Mar 2026 stood at 27500000.0 (down 68.82% YoY), while the FY2025 annual figure was 81557000.0, down 14.67% from the prior year.
- Income from Continuing Operations grew to 7849000.0 in Q1 2026 per IBIO's latest filing, from 9093000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2635000.0 in Q1 2024 and bottomed at 10563000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 6025352.94 across 5 years, with a median of 5074000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 79.75% — and 2025, when it sank 104.43%.
- iBio's Income from Continuing Operations stood at 10563000.0 in 2022, then surged by 57.51% to 4488000.0 in 2023, then advanced by 0.89% to 4448000.0 in 2024, then tumbled by 104.43% to 9093000.0 in 2025, then gained by 13.68% to 7849000.0 in 2026.
- Business Quant data shows IBIO's Income from Continuing Operations at 7849000.0 in Q1 2026, 9093000.0 in Q4 2025, and 5720000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.85 Mn |
| Dec 31, 2025 | -9.09 Mn |
| Sep 30, 2025 | -5.72 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Mar 31, 2025 | -4.95 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | -2.64 Mn |
| Dec 31, 2023 | -4.49 Mn |
| Sep 30, 2023 | -5.07 Mn |
| Jun 30, 2023 | -4.93 Mn |
| Mar 31, 2023 | -6.28 Mn |
| Dec 31, 2022 | -10.56 Mn |
| Sep 30, 2022 | -7.54 Mn |
| Jun 30, 2022 | -10.39 Mn |
| Mar 31, 2022 | -6.75 Mn |
| Dec 31, 2021 | -7.21 Mn |
| Sep 30, 2021 | -37.22 Mn |
| Jun 30, 2021 | -10.09 Mn |